This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 28/6/1200    most recent ATVBAHA.107.157172v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parini, P. Articles by Eriksson, M. Search for Related Content PubMed PubMed Citation Articles by Parini, P. Articles by Eriksson, M.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1200.)
© 2008 American Heart Association, Inc.

Clinical and Population Studies

Cholesterol Synthesis Inhibition Elicits an Integrated Molecular Response in Human Livers Including Decreased ACAT2

Paolo Parini; Ulf Gustafsson; Matt A. Davis; Lilian Larsson; Curt Einarsson; Martha Wilson; Mats Rudling; Hiroshi Tomoda; Satoshi mura; Staffan Sahlin; Bo Angelin; Lawrence L. Rudel; Mats Eriksson

From the Departments of Laboratory Medicine (P.P., L.L.), Biosciences and Nutrition (P.P., L.L., M.R., B.A., M.E.), Medicine (P.P., C.E., M.R., B.A., M.E.), and Surgery (U.G., S.S.), Karolinska Institutet, Stockholm, Sweden; the Department of Lipid Science (P.P., M.A.D., M.W., L.L.R.), Wake Forest University School of Medicine, Winston-Salem, NC; and Kitasato Institute for Life Sciences (H.T., S.O.), Kitasato University, Toyko, Japan.

Correspondence to Mats Eriksson, MD, PhD, Center for Endocrinology, Metabolism & Diabetes, Department of Medicine, Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden. E-mail mats.eriksson{at}karolinska.se

Objective— The purpose of this study was to identify how different degrees of cholesterol synthesis inhibition affect human hepatic cholesterol metabolism.

Methods and Results— Thirty-seven normocholesterolemic gallstone patients randomized to treatment with placebo, 20 mg/d fluvastatin, or 80 mg/d atorvastatin for 4 weeks were studied. Based on serum lathosterol determinations, cholesterol synthesis was reduced by 42% and 70% in the 2 groups receiving statins. VLDL cholesterol was reduced by 20% and 55%. During gallstone surgery, a liver biopsy was obtained and hepatic protein and mRNA expression of rate-limiting steps in cholesterol metabolism were assayed and related to serum lipoproteins. A marked induction of LDL receptors and 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase was positively related to the degree of cholesterol synthesis inhibition (ChSI). The activity, protein, and mRNA for ACAT2 were all reduced during ChSI, as was apoE mRNA. The lowering of HDL cholesterol in response to high ChSI could not be explained by altered expression of the HDL receptor CLA-1, ABCA1, or apoA-I.

Conclusions— Statin treatment reduces ACAT2 activity in human liver and this effect, in combination with a reduced Apo E expression, may contribute to the favorable lowering of VLDL cholesterol seen in addition to the LDL lowering during statin treatment.

Thirty-seven normocholesterolemic gallstone patients randomized to placebo, 20 mg/d fluvastatin, or 80 mg/d atorvastatin for 4 weeks were studied. Cholesterol synthesis in liver was reduced by 42% and 70% in the 2 groups receiving statins. Associated decreases in VLDL cholesterol of 20% and 55%, respectively, were shown. The activity, protein, and mRNA for hepatic ACAT2 were decreased in response to statins as was apoE mRNA.

Key Words: cholesterol • lipoprotein • liver • receptors • apolipoproteins

This article has been cited by other articles:

				J. Gronros, J. Wikstrom, U. Brandt-Eliasson, G. B. Forsberg, M. Behrendt, G. I. Hansson, and L. M. Gan Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2046 - H2053. [Abstract] [Full Text] [PDF]